Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2025
Association of a mild or an important decline in left ventricular ejection fraction with ventricular tachyarrhythmias, sudden cardiac death, and all-cause death in heart failure with preserved ejection fraction: a report from the CHART-2 Study.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ito Tomohiro, Noda Takashi, Nochioka Kotaro, Shiroto Takashi, Yamamoto Nobuhiko, Sato Hiroyuki, Hayashi Hideka, Chiba Takahiko, Nakano Makoto, Takahama Hiroyuki, Takahashi Jun, Miyata Satoshi, Shimokawa Hiroaki, Yasuda Satoshi
Аннотация
AIMS: A decline in left ventricular ejection fraction (LVEF) is often observed in patients with heart failure with preserved ejection fraction (HFpEF) and is associated with adverse outcomes. Although baseline LVEF is crucial for assessing the risk of sudden cardiac death in patients with HF, little is known about the relationship between the decline in LVEF and lethal arrhythmic events among patients with HFpEF.
METHODS AND RESULTS: We retrospectively analysed data from the CHART-2 Study. A total of 1453 patients with HF and LVEF ≥ 50% at registration (73 years, 39% female) were included and categorized into three groups based on their LVEF at the prespecified 1-year follow-up; 1316 with LVEF ≥ 50%, 120 with LVEF 36-50%, and 17 with LVEF ≤ 35%. The primary endpoint was a composite of ventricular tachycardia, ventricular fibrillation, and sudden cardiac death. All-cause death was also evaluated. During a median follow-up of 7.9 years, 79 (5.4%) patients experienced a composite event. Patients with LVEF < 50% at 1 year had a significantly higher incidence of the composite event (11.7 vs. 4.8%, P < 0.001), and all-cause death (62.8% vs. 51.8%, P = 0.006), compared to those with LVEF ≥ 50%. Importantly, a decline in LVEF to <50% was independently associated with an increased risk of the composite event (adjusted hazard ratio 1.99, 95% CI 1.04-3.79, P = 0.04).
CONCLUSION: In patients with HFpEF, even a mild decline in LVEF was associated with a higher risk of ventricular tachyarrhythmia, sudden cardiac death, and all-cause death. Continuous clinical assessment and re-evaluation of LVEF is crucial for the management of patients with HFpEF.
CLINICAL TRIAL REGISTRATION: https://www.clinicaltrials.gov; unique identifier: NCT00418041.
METHODS AND RESULTS: We retrospectively analysed data from the CHART-2 Study. A total of 1453 patients with HF and LVEF ≥ 50% at registration (73 years, 39% female) were included and categorized into three groups based on their LVEF at the prespecified 1-year follow-up; 1316 with LVEF ≥ 50%, 120 with LVEF 36-50%, and 17 with LVEF ≤ 35%. The primary endpoint was a composite of ventricular tachycardia, ventricular fibrillation, and sudden cardiac death. All-cause death was also evaluated. During a median follow-up of 7.9 years, 79 (5.4%) patients experienced a composite event. Patients with LVEF < 50% at 1 year had a significantly higher incidence of the composite event (11.7 vs. 4.8%, P < 0.001), and all-cause death (62.8% vs. 51.8%, P = 0.006), compared to those with LVEF ≥ 50%. Importantly, a decline in LVEF to <50% was independently associated with an increased risk of the composite event (adjusted hazard ratio 1.99, 95% CI 1.04-3.79, P = 0.04).
CONCLUSION: In patients with HFpEF, even a mild decline in LVEF was associated with a higher risk of ventricular tachyarrhythmia, sudden cardiac death, and all-cause death. Continuous clinical assessment and re-evaluation of LVEF is crucial for the management of patients with HFpEF.
CLINICAL TRIAL REGISTRATION: https://www.clinicaltrials.gov; unique identifier: NCT00418041.